PMID- 31821628
OWN - NLM
STAT- MEDLINE
DCOM- 20200519
LR  - 20200519
IS  - 1520-6777 (Electronic)
IS  - 0733-2467 (Linking)
VI  - 38 Suppl 5
DP  - 2019 Dec
TI  - How can we better manage drug-resistant OAB/DO? ICI-RS 2018.
PG  - S46-S55
LID - 10.1002/nau.24055 [doi]
AB  - AIMS: Botulinum toxin A (BTX-A), sacral nerve stimulation (SNM), and posterior 
      tibial nerve stimulation (PTNS) are established treatments for idiopathic 
      overactive bladder (OAB) refractory to oral drug therapy. At the ICI-RS meeting 
      in Bristol in 2018 a think tank was convened to address the question of how to 
      better manage drug-resistant OAB/DO (detrusor overactivity). METHODS: The think 
      tank conducted a literature review and an expert consensus meeting focusing on 
      the evidence for predicting response and adverse events (AEs) with the current 
      therapies for drug-resistant idiopathic OAB. RESULTS: Several factors have been 
      associated with poor outcomes using BTX-A including increasing age, body mass 
      index, male sex, and frailty. Voiding dysfunction with BTX-A also appears to be 
      more prevalent in those with increasing age, male sex, higher baseline postvoid 
      residual and with poorer contractility as assessed by urodynamic parameters. SNM 
      full implantation appears to be higher with the first stage tined lead placement 
      procedure compared to percutaneous nerve evaluation. Urodynamics do not appear to 
      predict outcomes with SNM. Patients with psychiatric comorbidity are more likely 
      to experience AEs with SNM. Outcomes related to lead positioning and the number 
      of active electrodes are mixed in predicting long term success. Patients with 
      increased daytime frequency and lower first sensation of bladder filling were 
      independent factors associated with success with PTNS. CONCLUSIONS: Further 
      research is required to optimize these procedures and to better understand which 
      patients will benefit from the various options available in managing refractory 
      OAB.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Chermansky, Christopher
AU  - Chermansky C
AUID- ORCID: 0000-0001-9444-4662
AD  - Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, 
      Pennsylvania.
FAU - Schurch, Brigitte
AU  - Schurch B
AUID- ORCID: 0000-0003-4965-6898
AD  - Department of Clinical Neurosciences, Neuropsychology and Neurorehabilitation 
      Service, Vaudois University Hospital of Lausanne, Lausanne, Switzerland.
FAU - Rahnama'i, Mohammad S
AU  - Rahnama'i MS
AUID- ORCID: 0000-0003-1953-7441
AD  - Department of Urology, University Hospital RWTH Aachen, Aachen, Germany.
AD  - Maastricht University, Maastricht, The Netherlands.
FAU - Averbeck, Marcio A
AU  - Averbeck MA
AUID- ORCID: 0000-0002-8127-7153
AD  - Department of Urology, Moinhos de Vento Hospital, Porto Alegre, Brazil.
FAU - Malde, Sachin
AU  - Malde S
AD  - Department of Urology, Guy's Hospital & King's College School of Medicine, 
      London, United Kingdom.
FAU - Mancini, Vito
AU  - Mancini V
AD  - Urology and Renal Transplant Unit, Ospedali Riuniti, University of Foggia, 
      Foggia, Italy.
FAU - Valentini, Francoise
AU  - Valentini F
AD  - Department of Physical Medicine and Rehabilitation, Hopital Rothschild, Paris, 
      France.
FAU - Sahai, Arun
AU  - Sahai A
AUID- ORCID: 0000-0003-4679-0506
AD  - Department of Urology, Guy's Hospital & King's College School of Medicine, 
      London, United Kingdom.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurourol Urodyn
JT  - Neurourology and urodynamics
JID - 8303326
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Botulinum Toxins, Type A/*therapeutic use
MH  - Electric Stimulation Therapy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Sex Factors
MH  - Tibial Nerve/physiopathology
MH  - Urinary Bladder, Overactive/drug therapy/physiopathology/*therapy
MH  - Urodynamics/physiology
OTO - NOTNLM
OT  - botulinum toxin
OT  - percutaneous tibial nerve stimulation
OT  - sacral neuromodulation
EDAT- 2019/12/11 06:00
MHDA- 2020/05/20 06:00
CRDT- 2019/12/11 06:00
PHST- 2019/02/16 00:00 [received]
PHST- 2019/03/31 00:00 [revised]
PHST- 2019/05/19 00:00 [accepted]
PHST- 2019/12/11 06:00 [entrez]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/05/20 06:00 [medline]
AID - 10.1002/nau.24055 [doi]
PST - ppublish
SO  - Neurourol Urodyn. 2019 Dec;38 Suppl 5:S46-S55. doi: 10.1002/nau.24055.